JMP reiterates Anadys at strong buy

Anadys Pharmaceuticals, Inc. was reiterated by JMP Securities analyst Adam Cutler at a strong buy rating. The company reported first-quarter loss per share of $0.20 versus JMP's at-consensus estimate of ($0.18). Preliminary data from the ANA975 28-day phase 1b trial in hepatitis C patients is expected in August. Shares of the San Diego, Calif., biopharmaceutical company were down $0.35 or 2.79%, at $12.19 on volume of 184,716 shares versus the three-month running average of 274,965 shares. (Nasdaq: ANDS)

Dendreon stays at market outperform by JMP

Dendreon Corp. was reiterated at market outperform and a $12 price target by JMP Securities analyst Charles C. Duncan. The company's financial results were somewhat in line with expectations. Revenues of $25,000 were below the analyst's estimate of $57,000. The net loss of $0.34 per share compared to JMP's and consensus projections of $0.37. Shares of the Seattle biotechnology company were down $0.12 or 2.96%, at $3.93 on volume of 783,614 shares versus the three-month running average of 781,776 shares. (Nasdaq: DNDN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.